At a public workshop in Washington, the FDA convened researchers and clinicians to confront a quiet paradox: testosterone therapy is already woven into the lives of many menopausal women, yet the science meant to justify and guide that practice remains largely unwritten. No FDA-approved formulation exists for this use, no diagnostic threshold defines deficiency in women, and the long-term safety record is, by the agency's own admission, a blank page. The question being asked is not whether women deserve relief from the burdens of menopause, but whether medicine has earned the right to offer th
ABC News - Breaking News, Latest News and Videos
· Sep 18, 2026
· health
· 2 min de lectura
High
Verificación: Verificado
FDA Scrutinizes Off-Label Testosterone Use for Menopause as Safety Questions Linger
◉
Health & Medicine
9645 artículos relacionados
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% coincidencia
American doctor in Congo confirmed with Ebola, transferred to Germany …
CBS News · 99% coincidencia
At-home flu vaccine now available in 34 states, removing barriers to v…
The Mercury News · 99% coincidencia
American Doctor Faces Ebola Crisis at Congo Hospital
Google News · 99% coincidencia
Kerala oncologist outlines breast cancer warning signs and self-exam s…
Malayala Manorama · 99% coincidencia
Cobertura Relacionada
NPR · Sep 19
Rising Temperatures Expand West Nile Virus Spread Across Italy
Italian health authorities link warming temperatures and extended warm seasons to increased West Nile virus transmission…
The Straits Times · Sep 19 Singapore Boy's Rare ZTTK Syndrome Diagnosis Highlights Early Intervention BenefitsA 2-year-old Singapore boy was diagnosed with ZTTK syndrome, a rare genetic disorder affecting brain development. Early …
Iran International · Sep 19 Death-row Iran protester denied hospital care despite urgent medical needFour years after Mahsa Amini's death sparked nationwide protests, Iran continues suppressing dissent with executions, ar…
Citizens Journal · Sep 19 Lotus Malaysia raises RM156k for childhood cancer support through anniversary campaignLotus Malaysia's fourth anniversary campaign raised RM156,305.23 for MAKNA to support children with cancer through bursa…
Sesgo y Encuadre
⚖
Article presents FDA concerns about off-label testosterone use in menopausal women with balanced scientific context, though emphasizes safety questions over potential benefits.
Bias Direction
center-left
Confidence
MED
Problem-focused framing emphasizing regulatory caution and unanswered safety questions rather than potential therapeutic benefits or patient demand drivers
safety questions linger
remain unanswered
cautioned
off-label use without FDA-approved formulations
key questions about long-term safety remain unanswered
Patient testimonials or experiences with testosterone therapy benefits
Perspectives from clinicians prescribing off-label testosterone and their clinical rationale
Data on adverse event rates or comparative safety profiles
Women's health advocates discussing access to treatments
Discussion of why FDA approval process for women's formulations has been limited
Impacto Geopolítico
🌎
FDA warns of unanswered safety questions regarding off-label testosterone use in menopausal women, with no approved formulations available in the U.S.
Escalation Risk
low
Confidence
HIGH
United States
This is a domestic regulatory matter with no significant geopolitical implications. It reflects FDA authority over pharmaceutical approvals and the tension between clinical practice and regulatory oversight within the U.S. healthcare system.
Lente Económico
📈
FDA warns of unanswered safety questions regarding off-label testosterone use in menopausal women, creating regulatory uncertainty for pharmaceutical and compounding pharmacy sectors.
Market Signal
bearish
Confidence
HIGH
Pharmaceutical Manufacturing
Compounding Pharmacies
Healthcare Services
Medical Devices
Biotech/Drug Development
Menopausal women currently using off-label testosterone may face treatment disruptions or increased costs if FDA restricts access; those seeking treatment may experience delayed access pending regulatory clarity and approved formulations.
FDA likely to establish formal guidance on testosterone use in women, potentially requiring clinical trials for approved formulations, stricter off-label prescribing standards, and standardized diagnostic protocols. May lead to new drug development requirements and compounding pharmacy regulations.